Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
LACOSAMIDE
MINT PHARMACEUTICALS INC
N03AX18
LACOSAMIDE
50MG
TABLET
LACOSAMIDE 50MG
ORAL
15G/50G
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0152810001; AHFS:
APPROVED
2019-07-15
_MINT-LACOSAMIDE, Lacosamide _ _Page 1 of 43_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MINT-LACOSAMIDE Lacosamide Tablets Tablets, 50 mg, 100 mg, 150 mg, 200 mg, Oral Manufacturer’s Standard Antiepileptic Agent ATC Code: N03AX18 Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Date of Initial Authorization: JUL 12, 2019 Date of Revision: JAN 12, 2023 Submission Control Number: 266694 _ _ _MINT-LACOSAMIDE, Lacosamide _ _Page 2 of 43_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, 7.1.1 Pregnant Women 01/2023 7 Warnings and Precautions, 7.1.2 Breast-feeding 01/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 4 4.1 Dosing Considerations ....................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment..................................................... 5 4.4 Administration................................................................................................... 6 4.5 Miss Přečtěte si celý dokument